MOH Molina Healthcare Inc.

Molina Healthcare Names Britt Travis as Vice President of Medicare Sales

Molina Healthcare, Inc. (NYSE: MOH) today announced that Britt Travis has joined the Company as its new vice president of Medicare sales. In this role, Travis will be responsible for Molina’s sales operations, overseeing the distribution strategy and execution as well as channel development and management in the states in which the Company offers its Medicare products.

Previously, Travis served as the vice president of distribution and sales at Highmark, Inc., a top-10 Medicare Advantage plan according to a Modern Healthcare report issued in March 2016 that ranked the nation’s largest Medicare Advantage plans. In this role, he was responsible for developing and executing growth and retention strategies for the Senior Markets Division. Under his leadership, Highmark was able to increase its Medicare net growth 8% year over year.

“With more than 30 years of Medicare experience and 25 years specifically in Medicare Advantage, Britt comes to us with a wealth of knowledge and experience,” said J. Mario Molina, M.D., president and chief executive officer of Molina Healthcare, Inc. “He has a proven track record of helping health care organizations improve their channel structure and overall sales performance, and we look forward to leveraging his expertise to continue growing our Medicare line of business.”

About Molina Healthcare, Inc.

Molina Healthcare, Inc., a FORTUNE 500 company, provides managed health care services under the Medicaid and Medicare programs and through the state insurance marketplaces. Through our locally operated health plans in 12 states across the nation and in the Commonwealth of Puerto Rico, Molina serves approximately 4.3 million members. Dr. C. David Molina founded our company in 1980 as a provider organization serving low-income families in Southern California. Today, we continue his mission of providing high quality and cost-effective health care to those who need it most. For more information about Molina Healthcare, please visit our website at molinahealthcare.com.

EN
16/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Molina Healthcare Inc.

Molina Healthcare Inc: 1 director

A director at Molina Healthcare Inc sold 1,500 shares at 322.885USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

Moody’s Ratings assigns a Ba2 rating to Molina’s new senior unsecured ...

New York , November 13, 2024 – Moody's Ratings (Moody's) has assigned a Ba2 rating to the new issuance of senior unsecured debt of Molina Healthcare, Inc. (Molina, NYSE: MOH). We anticipate the issuance, a private placement, to total $500 million and mature in 2033. The purpose is for general corpor...

Valens Research
  • Valens Research

MOH - Valens Credit Report - 2024 05 17

Cash bond markets are overstating MOH's credit risk with a YTW of 6.140% relative to an Intrinsic YTW of 5.170%, while CDS markets are accurately stating credit risk with a CDS of 112bps relative to an Intrinsic CDS of 81bps. Furthermore, Moody's is materially overstating MOH's fundamental credit risk with its highly speculative Ba2 credit rating seven notches below Valens' IG3+ (A1) credit rating. Incentives Dictate Behavior™ analysis highlights mostly negative signals for credit holders. As a...

Valens Research
  • Valens Research

MOH - Valens Credit Report - 2024 02 27

Cash bond markets are overstating MOH's credit risk with a YTW of 6.033% relative to an Intrinsic YTW of 5.103%, while CDS markets are slightly overstating credit risk with a CDS of 152bps relative to an Intrinsic CDS of 83bps. Furthermore, Moody's is grossly overstating MOH's fundamental credit risk with its highly speculative Ba3 credit rating eight notches below Valens' IG3+ (A1) credit rating. Incentives Dictate BehaviorTM analysis highlights mostly negative signals for credit holders. As a...

Valens Research
  • Valens Research

Valens Credit Weekly Insights - 2024 01 17

Valens Credit Research team highlights MOH, which has a compelling bond offering that we believe the market is currently mispricing, with strong fundamentals, favorable management alignment, and an actionable trade.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch